French scientists win $1 m. for results of treatment on mice with ALS

The successful results, in which the rodents’ lives were extended by more than 50%, surprised even the researchers.

February 2, 2017 16:26
1 minute read.

A mouse [illustrative].. (photo credit: INGIMAGE)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


A genetic treatment developed by French scientists for amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease, slows the advancement of the incurable neurological disease and has been called a “breakthrough” by Prize4Life, an organization founded in 2006 by a group of Harvard Business School students when one of them – Israeli Avi Kremer – was diagnosed with ALS.

Kremer, who was 29 years old when he was diagnosed with the disease, is still active in the organization, which is dedicated to accelerating research into the disease.

An ALS Treatment Prize of $1 million, named in honor of Kremer, will be awarded in April to the team of Dr.

Martine Barkats and Dr. Maria-Grazia Biferi of the Myologie Institute in Paris for their development of a gene therapy approach targeted at one of the most common known causes of inherited ALS.

This approach, tested pre-clinically on lab mice, significantly extends survival and slows disease progression beyond any results reported to date.

The treatment involves the “silencing” of a gene named SOD1. The experiment was repeated and proved successful when carried out at the ALS Therapy Development Institute in Cambridge, Massachusetts, according to Prize4Life.

The successful results, in which the rodents’ lives were extended by more than 50%, surprised even the researchers.

The treatment also significantly improved the motor functioning of the mice even after their ALS symptoms appeared.

The prize recipients said they were excited and satisfied by the promising results of their technique. “We are proud that we have helped speed up the way to developing a treatment using our new technique for dealing with the SOD1 gene,” they said, adding that they “look forward to its use in clinical trials.”

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

A wild sunflower
June 25, 2019
The unseen battle against the wild sunflower


Cookie Settings